A phase II, sham-controlled, double-blinded study testing the safety and efficacy of the coronary sinus reducer in patients with refractory angina: study protocol for a randomized controlled trial

Trials

Stefan Verheye¹  Elazer Edelman⁷  Christopher J White²  Serge Doucet⁵  Marc Schwartz³  Timothy D Henry⁴  Shmuel Banai⁶  E Marc Jolicœur⁵ 

[1] Antwerp Cardiovascular Institute, ZNA Middelheim Hospital, Lindendreef 1, 2020, Antwerpen 22, Belgium;The John Ochsner Heart & Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, 1514 Jefferson Highway, New Orleans, LA, 70121, USA;Neovasc, Inc., 137000 Mayfield Place, Richmond, BC V6V 2E4, Canada;Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, 920 East 28th Street, Minneapolis, MN, 55407, USA;Montreal Heart Institute, Université de Montréal, 5000 Bélanger Street East, Montréal, Québec Q H1T 1C8, Canada;The Tel Aviv Medical Center, The Tel Aviv University Medical School, 6 Weizman Street, Tel Aviv, 64239, Israel;Cardiovascular Division Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA

关键词: Reducer;    Coronary sinus;    Myocardial ischemia;    Advanced coronary artery disease;    Refractory angina;    Angina;   

Others  :  1094767
DOI  :  10.1186/1745-6215-14-46

 received in 2012-08-10, accepted in 2013-01-21,  发布年份 2013

【 摘 要 】

Background

A growing population of patients lives with severe coronary artery disease not amenable to coronary revascularization and with refractory angina despite optimal medical therapy. Percutaneous reduction of the coronary sinus is an emerging treatment for myocardial ischemia that increases coronary sinus pressure to promote a transcollateral redistribution of coronary artery in-flow from nonischemic to ischemic subendocardial territories. A first-in-man study has demonstrated that the percutaneous reduction of the coronary sinus can be performed safely in such patients. The COSIRA trial seeks to assess whether a percutaneous reduction of the coronary sinus can improve the symptoms of refractory angina in patients with limited revascularization options.

Methods/Design

The COSIRA trial is a phase II double-blind, sham-controlled, randomized parallel trial comparing the percutaneously implanted coronary sinus Reducer (Neovasc Inc, Richmond, BC, Canada) to a sham implantation in 124 patients enrolled in Canada, Belgium, England, Scotland, Sweden and Denmark. All patients need to have stable Canadian Cardiovascular Society (CCS) class III or IV angina despite optimal medical therapy, with evidence of reversible ischemia related to disease in the left coronary artery, and a left ventricular ejection fraction >25%. Participants experiencing an improvement in their angina ≥2 CCS classes six months after the randomization will meet the primary efficacy endpoint. The secondary objective of this trial is to test whether coronary sinus Reducer implantation will improve left ventricular ischemia, as measured by the improvement in dobutamine echocardiogram wall motion score index and in time to 1 mm ST-segment depression from baseline to six-month post-implantation.

Discussion

Based on previous observations, the COSIRA is expected to provide a significant positive result or an informative null result upon which rational development decisions can be based. Patient safety is a central concern and extensive monitoring should allow an appropriate investigation of the safety related to the coronary sinus Reducer.

Trial registration

ClinicalTrials.gov identifier - NCT01205893.

【 授权许可】

   
2013 Jolicoeur et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003, 41:159-168.
• [2]Jolicoeur EM, Granger CB, Henry TD, Stockbridge N, Smith S, Mark D, Califf RM, Henry TD, Chaitman BR, Granger CB, Working Group Members: Clinical and research issues regarding chronic advanced coronary artery disease: part I: contemporary and emerging therapies. Am Heart J 2008, 155:418-434.
• [3]Williams B, Menon M, Satran D, Hayward D, Hodges JS, Burke MN, Johnson RK, Poulose AK, Traverse JH, Henry TD: Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv 2010, 75:886-891.
• [4]Mukherjee D, Bhatt DL, Roe MT, Patel V, Ellis SG: Direct myocardial revascularization and angiogenesis-how many patients might be eligible? Am J Cardiol 1999, 84:A8-A600.
• [5]Paz Y, Shinfeld A: Mild increase in coronary sinus pressure with coronary sinus reducer stent for treatment of refractory angina. Nat Clin Pract Cardiovasc Med 2009, 6:E3.
• [6]Beck CS, Leighninger DS: Operations for coronary artery disease. J Am Med Assoc 1954, 156:1226-1233.
• [7]Beck CS, Leighninger DS: Scientific basis for the surgical treatment of coronary artery disease. J Am Med Assoc 1955, 159:1264-1271.
• [8]Sandler G, Slesser BV, Lawson CW: The Beck operation in the treatment of angina pectoris. Thorax 1967, 22:34-37.
• [9]Wising PJ: The Beck-I operation for angina pectoris: medical aspects. Acta Med Scand 1963, 174:93-98.
• [10]Brofman BL: Medical evaluation of the Beck operation for coronary artery disease. J Am Med Assoc 1956, 162:1603-1606.
• [11]Camici PG, Crea F: Coronary microvascular dysfunction. N Engl J Med 2007, 356:830-840.
• [12]Ido A, Hasebe N, Matsuhashi H, Kikuchi K: Coronary sinus occlusion enhances coronary collateral flow and reduces subendocardial ischemia. Am J Physiol Heart Circ Physiol 2001, 280:H1361-H1367.
• [13]Banai S, Ben MS, Parikh KH, Medina A, Sievert H, Seth A, Tsehori J, Paz Y, Sheinfeld A, Keren G: Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study. J Am Coll Cardiol 2007, 49:1783-1789.
• [14]Banai S, Schwart M, Sievert H, Seth A, Keren G, Parikh KH: Long-term follow-up to evaluate the safety of the neovasc reducer, a device-based therapy for chronic refractory angina. J Am Coll Cardiol 2010, 55:A98.E927.
• [15]McGillion M, Arthur HM, Cook A, Carroll SL, Victor JC, L'allier PL, Jolicoeur EM, Svorkdal N, Niznick J, Teoh K, Cosman T, Sessle B, Watt-Watson J, Clark A, Taenzer P, Coyte P, Malysh L, Galte C, Stone J: Management of patients with refractory angina: Canadian cardiovascular society/Canadian pain society joint guidelines. Can J Cardiol 2012, Suppl 2:S20-S41.
• [16]Jolicoeur EM, Cartier R, Henry TD, Barsness GW, Bourassa MG, McGillion M, L'Allier PL: Patients with coronary artery disease unsuitable for revascularization: definition, general principles, and a classification. Can J Cardiol 2012, Suppl 2:S50-S59.
• [17]Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001, 134:657-662.
• [18]Chaitman BR, Stone PH, Knatterud GL, Forman SA, Sopko G, Bourassa MG, Pratt C, Rogers WJ, Pepine CJ, Conti CR, The ACIP Investigators: Asymptomatic Cardiac Ischemia Pilot (ACIP) study: impact of anti-ischemia therapy on 12-week rest electrocardiogram and exercise test outcomes. J Am Coll Cardiol 1995, 26:585-593.
• [19]Frolicher VF, Myers J: Manual of Exercise Testing 3rd edition. Philadelphia: Mosby Elsevier; 2007.
• [20]Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, Fihn : Development and evaluation of the Seattle Angina questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 1995, 25:333-341.
• [21]Friedrich MG, Niendorf T, Schulz-Menger J, Gross CM, Dietz R: Blood oxygen level-dependent magnetic resonance imaging in patients with stress-induced angina. Circulation 2003, 108:2219-2223.
• [22]Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Traverse JH, Amrani D, Ewenstein BM, Riedel N, Story K, Barker K, Povsic TJ, Harrington RA, Schatz RA, ACT34-CMI Investigators: Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res 2011, 109:428-436.
• [23]Vickers AJ, Altman DG: Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 2001, 323:1123-1124.
• [24]Knoke JD: Nonparametric analysis of covariance for comparing change in randomized studies with baseline values subject to error. Biometrics 1991, 47:523-533.
• [25]Von LM: The venous drainage of the human myocardium. Adv Anat Embryol Cell Biol 2003, 168:1-104.
• [26]Parmar RC, Kulkarni S, Nayar S, Shivaraman A: Coronary sinus thrombosis. J Postgrad Med 2002, 48:312-313.
• [27]Neri E, Tripodi A, Tucci E, Capannini G, Sassi C: Dramatic improvement of LV function after coronary sinus thromboembolectomy. Ann Thorac Surg 2000, 70:961-963.
• [28]Jolicoeur EM, Ohman EM, Temple R, Swain J, Stockbridge N, Witten C, Smith S, Mark D, Califf RM, Henry TD, Chaitman BR, Granger CB: Clinical and research issues regarding chronic advanced coronary artery disease part II: trial design, outcomes, and regulatory issues. Am Heart J 2008, 155:435-444.